236 lines
48 KiB
Text
236 lines
48 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548897">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548897/?report=reader">
|
|
<meta name="ncbi_pagename" content="Aprepitant - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Aprepitant - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Apremilast/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Arecacatechu/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Aprepitant">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2024/02/28">
|
|
<meta name="citation_pmid" content="31644204">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548897/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Aprepitant">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2024/02/28">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548897/">
|
|
<meta name="description" content="Aprepitant and its prodrug fosaprepitant are antiemetic agents that are used to prevent cancer chemotherapy related nausea and vomiting. Both aprepitant and fosaprepitant are associated with a low rate of serum enzyme elevations after treatment which are similar to rates with comparator therapies, and neither agent has been clearly linked to cases of clinically apparent liver injury with jaundice.">
|
|
<meta name="og:title" content="Aprepitant">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Aprepitant and its prodrug fosaprepitant are antiemetic agents that are used to prevent cancer chemotherapy related nausea and vomiting. Both aprepitant and fosaprepitant are associated with a low rate of serum enzyme elevations after treatment which are similar to rates with comparator therapies, and neither agent has been clearly linked to cases of clinically apparent liver injury with jaundice.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548897/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Aprepitant/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548897/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DB1A37D7B04F100000000010300D5.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548897/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Apremilast/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Aprepitant</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Arecacatechu/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548897/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548897/&text=Aprepitant"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548897/?report=classic">Switch to classic view</a><a href="/books/NBK548897/pdf/Bookshelf_NBK548897.pdf">PDF (110K)</a><a href="/books/NBK548897/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548897%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DB1A37D7B04F100000000010300D5.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548897_"><span class="title" itemprop="name">Aprepitant</span></h1><p class="fm-aai"><a href="#_NBK548897_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Aprepitant.OVERVIEW"><h2 id="_Aprepitant_OVERVIEW_">OVERVIEW</h2><div id="Aprepitant.Introduction"><h3>Introduction</h3><p>Aprepitant and its prodrug fosaprepitant are antiemetic agents that are used to prevent cancer chemotherapy related nausea and vomiting. Both aprepitant and fosaprepitant are associated with a low rate of serum enzyme elevations after treatment which are similar to rates with comparator therapies, and neither agent has been clearly linked to cases of clinically apparent liver injury with jaundice.</p></div><div id="Aprepitant.Background"><h3>Background</h3><p>Aprepitant (a pre’ pi tant) is a substance P antagonist that blocks the neurokinin 1 (NK1) receptor, which is found in the central nervous system and induces the vomiting reflex when activated by its ligand, substance P. Aprepitant has been shown to inhibit both acute and delayed nausea and vomiting associated with cancer chemotherapy and surgical procedures. It appears to act synergistically with serotonin type 3 (5-HT3) receptor blockers. Aprepitant was approved for use in the United States in 2003 and its prodrug fosaprepitant in 2008. Current indications are for prevention of nausea and vomiting after highly or moderately emetogenic chemotherapy regimens. Aprepitant is available as 40, 80 and 125 mg capsules generically and under the brand name Emend. The typical dose regimen of aprepitant for prevention of nausea and vomiting after cancer chemotherapy is 125 mg given one hour before chemotherapy in combination with a 5-HT3 receptor blocker and dexamethasone (12 mg orally), followed by a lower dose of aprepitant (80 mg) on days 2 and 3 along with a lower dose of dexamethasone (8 mg) orally on days 2, 3 and 4. Dose regimens are slightly different for children, and for moderately emetogenic chemotherapy regimens, and for prevention of postoperative nausea and vomiting. Fosaprepitant, the prodrug of aprepitant, has similar clinical effects, side effects and metabolism, and is available as a lyophilized powder for reconstitution in single use vials of 150 mg generically and under the brand name Emend. It is given as a single intravenous infusion of 150 mg started 30 minutes before chemotherapy in combination with an intravenous 5-HT3 receptors blocker and dexamethasone given orally in a manner similar to aprepitant. Common side effects of aprepitant and fosaprepitant include fatigue, drowsiness, dizziness, headache, diarrhea and abdominal discomfort. Infusion reactions are not uncommon with fosaprepitant but rarely severe, although cases of anaphylaxis and Stevens Johnson syndrome have been described.</p></div><div id="Aprepitant.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In preregistration clinical trials of aprepitant, serum aminotransferase elevations occurred in 6% of treated patients compared to 4.3% in controls receiving cancer chemotherapy. The aminotransferase elevations were transient, mild-to-moderate in severity, and not associated with symptoms or jaundice. There have been no convincing cases of clinically apparent liver injury attributable to aprepitant or fosaprepitant published in the literature and thus, significant liver injury from their use must be exceedingly rare if it occurs at all.</p><p>Likelihood score: E (unlikely causes of clinically apparent liver injury).</p></div><div id="Aprepitant.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The serum aminotransferase elevations that occur after aprepitant therapy are more likely due to the chemotherapy rather than the antiemetic. The lack of reported cases of liver injury due to aprepitant and fosaprepitant may be due to the low doses and short duration of typical therapy. Aprepitant is metabolized by and inhibits hepatic CYP 3A4 and has the potential to cause significant drug-drug interactions. It also has significant interactions with warfarin and with hormonal contraceptives.</p><p>Drug Class: <a href="/books/n/livertox/GastrointestinalAgen/?report=reader">Gastrointestinal Agents</a>, <a href="/books/n/livertox/AntiemeticAgents/?report=reader">Antiemetic Agents</a></p><p>Other Drugs in the Subclass, Substance P/Neurokinin-1 Receptor Antagonists: <a href="/books/n/livertox/Fosnetupitant/?report=reader">Fosnetupitant</a>, <a href="/books/n/livertox/Rolapitant/?report=reader">Rolapitant</a></p></div></div><div id="Aprepitant.PRODUCT_INFORMATION"><h2 id="_Aprepitant_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Aprepitant – Generic, Emend®</p><p>Fosaprepitant – Emend®</p><p>
|
|
<b>DRUG CLASS</b></p><p>Gastrointestinal Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aprepitant" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Aprepitant.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Aprepitant_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figAprepitantTc"><a href="/books/NBK548897/table/Aprepitant.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figAprepitantTc" rid-ob="figobAprepitantTc"><img class="small-thumb" src="/books/NBK548897/table/Aprepitant.Tc/?report=thumb" src-large="/books/NBK548897/table/Aprepitant.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Aprepitant.Tc"><a href="/books/NBK548897/table/Aprepitant.Tc/?report=objectonly" target="object" rid-ob="figobAprepitantTc">Table</a></h4></div></div></div><div id="Aprepitant.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Aprepitant_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 28 February 2024</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Aprepitant.REF.zimmerman.1999">Zimmerman HJ. Antiemetic and prokinetic compounds. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 721.<div><i>(Expert review of hepatotoxicity published in 1999 before the availability of NK1 antagonists such as aprepitant).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.sharkey.2018">Sharkey KA, McNaughton WK. Gastrointestinal motility and water flux, emesis, and biliary and pancreatic disease. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 921-44.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.navari.2004.715">Navari
|
|
RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004;4:715–724.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15485308" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15485308</span></a>]<div><i>(Review of the structure, pharmacokinetics, metabolism, mechanism of action, efficacy and safety of aprepitant mentions that adverse events may include fatigue, anorexia, constipation, diarrhea, nausea, and hiccups, but the rate of adverse events is not increased by adding aprepitant to standard preventive regimens).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.polibigelli.2003.3090">Poli-Bigelli
|
|
S, Rodrigues-Pereira
|
|
J, Carides
|
|
AD, Julie Ma
|
|
G, Eldridge
|
|
K, Hipple
|
|
A, Evans
|
|
JK, et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12784346" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12784346</span></a>]<div><i>(Among 523 patients with cancer treated with ondansetron and dexamethasone with or without aprepitant to prevent nausea and vomiting after chemotherapy, nausea and vomiting was less with aprepitant, but side effects were similar in the two groups including rates of ALT and AST elevations above 5 times ULN [actual rates not provided]).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.gralla.2005.864">Gralla
|
|
RJ, de Wit
|
|
R, Herrstedt
|
|
J, Carides
|
|
AD, Ianus
|
|
J, Guoguang-Ma
|
|
J, Evans
|
|
JK, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104:864–868.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15973669" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15973669</span></a>]<div><i>(Analysis of results from two large studies in more than 1000 cancer patients who received aprepitant vs placebo in addition to ondansetron and dexamethasone during chemotherapy; both early and delayed nausea and vomiting were decreased in those receiving aprepitant in comparison to controls; no mention of side effects, hepatotoxicity or ALT levels).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.jordan.2009.1184">Jordan
|
|
K, Kinitz
|
|
I, Voigt
|
|
W, Behlendorf
|
|
T, Wolf
|
|
HH, Schmoll
|
|
HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer. 2009;45:1184–1187.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19135359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19135359</span></a>]<div><i>(Among 78 patients with cancer treated with aprepitant, granisetron and dexamethasone to prevent the nausea and vomiting of cancer chemotherapy, side effects were largely attributed to the antineoplastic agents; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.reuben.2010.2065">Reuben
|
|
A, Koch
|
|
DG, Lee
|
|
WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–2076.
|
|
[<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to an antiemetic agent).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.ferrajolo.2010.721">Ferrajolo
|
|
C, Capuano
|
|
A, Verhamme
|
|
KM, Schuemie
|
|
M, Rossi
|
|
F, Stricker
|
|
BH, Sturkenboom
|
|
MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70:721–728.
|
|
[<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21039766" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Among 624,673 adverse event reports in children between 2000 and 2006 in the WHO VigiBase, 1% were hepatic but no antiemetic was listed among the 41 most commonly implicated agents).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.jordan.2011.784">Jordan
|
|
K, Jahn
|
|
F, Jahn
|
|
P, Behlendorf
|
|
T, Stein
|
|
A, Ruessel
|
|
J, Kegel
|
|
T, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46:784–789.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20838387" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20838387</span></a>]<div><i>(Among 64 patients with cancer treated with aprepitant, dexamethasone and granisetron to prevent chemotherapy induced nausea and vomiting, side effects were largely due to the antineoplastic agents; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.bj_rnsson.2013.1419">Björnsson
|
|
ES, Bergmann
|
|
OM, Björnsson
|
|
HK, Kvaran
|
|
RB, Olafsson
|
|
S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to antiemetics).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.saito.2013.1067">Saito
|
|
H, Yoshizawa
|
|
H, Yoshimori
|
|
K, Katakami
|
|
N, Katsumata
|
|
N, Kawahara
|
|
M, Eguchi
|
|
K. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24:1067–1073.
|
|
[<a href="/pmc/articles/PMC3603438/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3603438</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23117073" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23117073</span></a>]<div><i>(Among 347 patients with cancer treated with granisetron and dexamethasone with or without fosaprepitant to prevent nausea and vomiting after cisplatin based chemotherapy, side effects were similar between the two groups; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.stiff.2013.49">Stiff
|
|
PJ, Fox-Geiman
|
|
MP, Kiley
|
|
K, Rychlik
|
|
K, Parthasarathy
|
|
M, Fletcher-Gonzalez
|
|
D, Porter
|
|
N, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19:49–55.e1.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22863840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22863840</span></a>]<div><i>(Among 181 patients undergoing hematopoietic cell transplantation for malignant disease who received ondansetron and dexamethasone with either aprepitant or placebo to prevent chemotherapy induced nausea and vomiting, nausea was less with aprepitant, but other side effects were similar in the two groups, although 5 died in the aprepitant arm [one from toxic epidermal necrolysis and one from sinusoidal obstruction syndrome] compared to only 2 in the control group).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.hern_ndez.2014.231">Hernández
|
|
N, Bessone
|
|
F, Sánchez
|
|
A, di Pace
|
|
M, Brahm
|
|
J, Zapata
|
|
RA, Chirino
|
|
R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol. 2014;13:231–239.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, the most common implicated agents being nimesulide [n=53: 30%], cyproterone [n=18], nitrofurantoin [n=17], antituberculosis drugs [n=13] and flutamide [n=12: 7%]; no antiemetic was listed).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.chalasani.2015.1340">Chalasani
|
|
N, Bonkovsky
|
|
HL, Fontana
|
|
R, Lee
|
|
W, Stolz
|
|
A, Talwalkar
|
|
J, Reddy
|
|
KR, et al; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology. 2015;148:1340–52.e7.
|
|
[<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to aprepitant or other antiemetic agents).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF15">IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting. Med Lett Drugs Ther. 2018;60:e200–e201.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30653479" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30653479</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety, and costs of aprepitant, the first substance P inhibitor approved for prevention of nausea and vomiting after highly emetogenic chemotherapy; in discussion of adverse events, no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.aapro.2021.103143">Aapro
|
|
M, Navari
|
|
RM, Roeland
|
|
E, Zhang
|
|
L, Schwartzberg
|
|
L. Efficacy of intravenous NEPA, a fixed NK/5-HT receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: a review of phase 3 studies. Crit Rev Oncol Hematol. 2021;157:103143.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33260048" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33260048</span></a>]<div><i>(Analysis of 15 studies of NK-1 receptor inhibitors compared to 5-HT3 receptor inhibitors, including 2077 patients treated with both fosnetupitant and palonosetron [NEPA], 403 orally and 1674 intravenously [iv], the overall complete response with cisplatin regimens was 77% for iv NEPA, which was similar for oral NEPA [75-90%], and was higher than that with other NK-1/5-HT3 combinations [66-78%], mentions that NK-1 inhibitors were “safe and well tolerated”; no discussion of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.hata.2022.180">Hata
|
|
A, Okamoto
|
|
I, Inui
|
|
N, Okada
|
|
M, Morise
|
|
M, Akiyoshi
|
|
K, Takeda
|
|
M, et al. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40:180–188.
|
|
[<a href="/pmc/articles/PMC8718175/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8718175</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34793245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34793245</span></a>]<div><i>(Among 795 patients treated with iv fosnetupitant or fosaprepitant combined with iv palonosetron and 4 days of oral dexamethasone, the complete response rates were 75% vs 71% and treatment related adverse event rates 22% vs 25%, while injection site reactions were less with NEPA [11% vs 21%]).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.zhang.2020.234">Zhang
|
|
Z, Yang
|
|
Y, Lu
|
|
P, Li
|
|
X, Chang
|
|
J, Zheng
|
|
R, Zhou
|
|
L. Cet al. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. Ann Transl Med. 2020;8:234.
|
|
[<a href="/pmc/articles/PMC7154406/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7154406</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32309381" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32309381</span></a>]<div><i>(Among 644 Chinese adults receiving cisplatin based chemotherapy who were treated with palonosetron and dexamethasone with either fosaprepitant [single 150 mg iv dose] or aprepitant [orally for 3 days as 125 , 80, and 80 mg], rates of complete response were similar [72% vs 67%] as were total adverse events [85% vs 84%] and serious adverse events [1.9% vs 2.5%, all considered “unrelated”], and side effects were similar in the two groups; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.wang.2021.e215250">Wang
|
|
DS, Hu
|
|
MT, Wang
|
|
ZQ, Ren
|
|
C, Qiu
|
|
MZ, Luo
|
|
HY, Jin
|
|
Y, et al. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021;4:e215250.
|
|
[<a href="/pmc/articles/PMC8035650/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8035650</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33835174" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33835174</span></a>]<div><i>(Among 248 women receiving cancer chemotherapy treated with palonosetron and dexamethasone with either oral aprepitant for 3 days [125, 80 and 80 mg] or placebo, complete response [no emesis or rescue therapy] rates were 87% vs 67% and adverse event rates were similar with no serious adverse events attributable to the antiemetics; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.matsuura.2022.1692">Matsuura
|
|
K, Tsurutani
|
|
J, Inoue
|
|
K, Tanabe
|
|
Y, Taira
|
|
T, Kubota
|
|
K, Tamura
|
|
T, et al. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022;128:1692–1698.
|
|
[<a href="/pmc/articles/PMC9306508/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9306508</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35045185" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35045185</span></a>]<div><i>(Among 102 patients treated with iv fosnetupitant or fosaprepitant in combination with palonosetron before receiving cancer chemotherapy, the complete response rate was 46% vs 51% and treatment related adverse event rates were similar [21% vs 22%], although injection site reactions were less frequent with fosnetupitant [6% vs 26%]).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.dranitsaris.2022.6649">Dranitsaris
|
|
G, Moezi
|
|
M, Dobson
|
|
K, Phelan
|
|
R, Blau
|
|
S. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2022;30:6649–6658.
|
|
[<a href="/pmc/articles/PMC9213362/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9213362</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35499619" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35499619</span></a>]<div><i>(Among 294 adults receiving prophylaxis for nausea and vomiting for cancer chemotherapy in 17 community hospitals, those receiving fosaprepitant had slightly lower rates of control of nausea and vomiting and higher rates of infusion reactions compared to those receiving fosnetupitant, while most other adverse event rates were similar; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Aprepitant.REF.yu.2024.110">Yu
|
|
LT, Wang
|
|
Z, Han
|
|
YL, Zhou
|
|
F, Wagner
|
|
LM, Zhang
|
|
SG, Li
|
|
ZL, et al. Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial. Transl Pediatr. 2024;13:110–118.
|
|
[<a href="/pmc/articles/PMC10839286/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10839286</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38323173" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38323173</span></a>]<div><i>(Among 108 Chinese children receiving cancer chemotherapy treated with ondansetron and dexamethasone with either a single infusion of fosaprepitant or 3 days of oral aprepitant, the control of early nausea and vomiting [day 1] was higher with fosaprepitant [95% vs 79%] but not for combined early and late [days 1-5] symptoms [71% vs 67%], and adverse event rates were similar and largely due to the chemotherapy; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548897_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">February 28, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Aprepitant. [Updated 2024 Feb 28].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Apremilast/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Arecacatechu/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobAprepitantTc"><div id="Aprepitant.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548897/table/Aprepitant.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Aprepitant.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Aprepitant.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Aprepitant.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Aprepitant.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Aprepitant.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Aprepitant.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">Aprepitant</td><td headers="hd_h_Aprepitant.Tc_1_1_1_2" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135106950" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">170729-80-3</a>
|
|
</td><td headers="hd_h_Aprepitant.Tc_1_1_1_3" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">C23-H21-F7-N4-O3</td><td headers="hd_h_Aprepitant.Tc_1_1_1_4" rowspan="1" colspan="1" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt;text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135106950" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135106950" alt="image 135106950 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|